Longboard Pharmaceuticals Announces the Appointment of Highly Accomplished Healthcare Executive Randall Kaye, M.D., as Chief Medical Officer
March 21, 2022 16:01 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results
March 03, 2022 16:05 ET
|
Longboard Pharmaceuticals, Inc.
Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs)LP352 demonstrated statistically significant reduction of epileptiform...
Longboard Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
January 05, 2022 08:30 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
Longboard Pharmaceuticals Appoints Brandi L. Roberts as Chief Financial Officer
January 21, 2021 08:30 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological...
Longboard Pharmaceuticals Appoints Phillip Schneider and Paul Sekhri to Board of Directors
January 20, 2021 16:30 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological...